(VIANEWS) – Catalyst Pharmaceuticals (CPRX), Vertex (VERX), The Simply Good Foods Company (SMPL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Catalyst Pharmaceuticals (CPRX)
20.4% sales growth and 14.55% return on equity
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
Earnings Per Share
As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of $0.63.
PE Ratio
Catalyst Pharmaceuticals has a trailing twelve months price to earnings ratio of 24.16. Meaning, the purchaser of the share is investing $24.16 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.55%.
2. Vertex (VERX)
13.8% sales growth and 3.26% return on equity
The zacks analyst blog vertex pharmaceuticals crispr and ModernaStocks recently featured in the blog include: Vertex Pharmaceuticals Incorporated (VRTX Quick QuoteVRTX – Free Report) , CRISPR Therapeutics’ (CRSP Quick QuoteCRSP – Free Report) and Moderna (MRNA Quick QuoteMRNA – Free Report) ., While CF remains the main area of focus, Vertex has seen rapid success in its non-CF pipeline candidates’ development in the past year.
Vertex, Inc. provides tax technology solutions for corporations in retail, leasing, communication, and manufacturing industries in the United States and internationally. It offers tax determination, compliance and reporting, tax data management, document management, pre-built integration, and industry-specific solutions. The company sells its software products through software license and software as a service subscriptions. It also offers implementation and training services in connection with its software license and cloud subscriptions, transaction tax returns outsourcing, and other tax-related services. The company was founded in 1978 and is headquartered in King of Prussia, Pennsylvania.
Earnings Per Share
As for profitability, Vertex has a trailing twelve months EPS of $0.05.
PE Ratio
Vertex has a trailing twelve months price to earnings ratio of 724.2. Meaning, the purchaser of the share is investing $724.2 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.26%.
Previous days news about Vertex(VERX)
- According to Zacks on Tuesday, 6 August, "In the year-ago quarter, the company generated collaboration revenues worth $70 million, which comprised a research milestone payment from Vertex Pharmaceuticals (VRTX Quick QuoteVRTX – Free Report) ."
- Here's how to play vertex (vrtx) stock after Q2 loss, price dip. According to Zacks on Thursday, 8 August, "Based on a strong performance in the first half, Vertex raised its total product sales guidance from a range of $10.55-$10.75 billion to $10.65-$10.85 billion for 2024.", "It can potentially treat CF patients who have discontinued Trikafta or other Vertex CF medicines. "
3. The Simply Good Foods Company (SMPL)
13.1% sales growth and 9.1% return on equity
The Simply Good Foods Company operates as a consumer packaged food and beverage company in North America and internationally. The company develops, markets, and sells snacks and meal replacements. It offers primarily nutrition bars, ready-to-drink (RTD) shakes, sweet and salty snacks, protein bars, cookies, pizza, protein chips, recipes, and confectionery products, as well as licensed frozen meals under the Atkins, Atkins Endulge, and Quest brand names. The company distributes its products to various retail channels, such as mass merchandise, grocery and drug channels, club stores, convenience stores, gas stations, and other channels. It also sells its products through e-commerce channels, including atkins.com, questnutrition.com, and amazon.com. The Simply Good Foods Company is headquartered in Denver, Colorado.
Earnings Per Share
As for profitability, The Simply Good Foods Company has a trailing twelve months EPS of $1.45.
PE Ratio
The Simply Good Foods Company has a trailing twelve months price to earnings ratio of 23.79. Meaning, the purchaser of the share is investing $23.79 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.1%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 11.1% and 4.7%, respectively.
4. Grifols, S.A. (GRFS)
8.3% sales growth and 3.48% return on equity
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Earnings Per Share
As for profitability, Grifols, S.A. has a trailing twelve months EPS of $0.1.
PE Ratio
Grifols, S.A. has a trailing twelve months price to earnings ratio of 77.4. Meaning, the purchaser of the share is investing $77.4 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.48%.
Volume
Today’s last reported volume for Grifols, S.A. is 1281050 which is 15.05% below its average volume of 1508150.
Moving Average
Grifols, S.A.’s value is higher than its 50-day moving average of $7.42 and below its 200-day moving average of $7.99.
Sales Growth
Grifols, S.A.’s sales growth is 7.8% for the current quarter and 8.3% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 4.1%, now sitting on 6.66B for the twelve trailing months.
5. Federal Signal Corporation (FSS)
7.7% sales growth and 19.98% return on equity
Federal Signal Corporation, together with its subsidiaries, designs, manufactures, and supplies a suite of products and integrated solutions for municipal, governmental, industrial, and commercial customers in the United States, Canada, Europe, and internationally. It operates through Environmental Solutions Group, and Safety and Security Systems Group. The Environmental Solutions Group segment offers a range of street sweepers, safe-digging trucks ,sewer cleaners, industrial vacuum loaders, vacuum, and hydro-excavation trucks; road-marking, line-removal and waterblasting equipment, dump truck bodies, trailers, and metal extraction support equipment under the Elgin, Vactor, Guzzler, TRUVAC, Westech, Jetstream, Mark Rite Lines, Ox Bodies, Crysteel, J-Craft, Duraclass, Rugby, Travis, OSW, NTE, WTB, Ground Force, Bucks, and Switch-N-Go brand names. It also offers refuse and recycling collection vehicles, camera systems, ice resurfacing equipment, and snow-removal equipment, as well as safety, and security systems. In addition, this segment engages in the sale of parts, service and repair, equipment rental, and training activities. The Safety and Security Systems Group segment provides systems and products for community alerting, emergency vehicles, first responder interoperable communications, and industrial communications. Its products include vehicle lightbars and sirens, industrial signaling equipment, public warning systems, general alarm systems, and public address systems. This segment sells its products under the Federal Signal, Federal Signal VAMA, and Victor brand names. The company sells its products through wholesaler, distributor, independent manufacturer representative, original equipment manufacturer, and direct sales force, as well as independent foreign distributor. Federal Signal Corporation was founded in 1901 and is headquartered in Oak Brook, Illinois.
Earnings Per Share
As for profitability, Federal Signal Corporation has a trailing twelve months EPS of $3.28.
PE Ratio
Federal Signal Corporation has a trailing twelve months price to earnings ratio of 27.73. Meaning, the purchaser of the share is investing $27.73 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.98%.
